MAP2K7 and melanoma: Since 2011 the prognosis of systemic melanoma has profoundly changed with the introduction of new targeted therapies, as BRAF inhibitors and MEK inhibitors and immunotherapy (anti-CTLA-4 and anti-PD-1).